Combination Therapy: How to optimize drug synergies and disease modulation?

๐—–๐—ผ๐—บ๐—ฏ๐—ถ๐—ป๐—ฎ๐˜๐—ถ๐—ผ๐—ป ๐—ง๐—ต๐—ฒ๐—ฟ๐—ฎ๐—ฝ๐˜†: ๐—›๐—ผ๐˜„ ๐˜๐—ผ ๐—ผ๐—ฝ๐˜๐—ถ๐—บ๐—ถ๐˜‡๐—ฒ ๐—ฑ๐—ฟ๐˜‚๐—ด ๐˜€๐˜†๐—ป๐—ฒ๐—ฟ๐—ด๐—ถ๐—ฒ๐˜€ ๐—ฎ๐—ป๐—ฑ ๐—ฑ๐—ถ๐˜€๐—ฒ๐—ฎ๐˜€๐—ฒ ๐—บ๐—ผ๐—ฑ๐˜‚๐—น๐—ฎ๐˜๐—ถ๐—ผ๐—ปโ“

Pathway profiling is powerful for quantifying monitoring disease modulation. Quantify 800 proteins per sample and get all data you need for drug repurposing, combination therapy optimization, and drug resistance analysis.

Request the latest Hyperplexโ„ข assay menu now and customize your pathway profiling assay from pre-validated antibody panels (total and phospho-protein).

๐—ฅ๐—ฒ๐—พ๐˜‚๐—ฒ๐˜€๐˜ ๐˜๐—ต๐—ฒ ๐—น๐—ฎ๐˜๐—ฒ๐˜€๐˜ ๐—›๐˜†๐—ฝ๐—ฒ๐—ฟ๐—ฝ๐—น๐—ฒ๐˜…โ„ข ๐—ฎ๐˜€๐˜€๐—ฎ๐˜† ๐—บ๐—ฒ๐—ป๐˜‚ ๐—ฎ๐˜ partnering@assay-engineers.com ๐—ฎ๐—ป๐—ฑ ๐—ฐ๐˜‚๐˜€๐˜๐—ผ๐—บ๐—ถ๐˜‡๐—ฒ ๐˜†๐—ผ๐˜‚๐—ฟ ๐—ฝ๐—ฎ๐˜๐—ต๐˜„๐—ฎ๐˜† ๐—ฝ๐—ฟ๐—ผ๐—ณ๐—ถ๐—น๐—ถ๐—ป๐—ด ๐—ฎ๐˜€๐˜€๐—ฎ๐˜† ๐—ณ๐—ฟ๐—ผ๐—บ ๐—ฝ๐—ฟ๐—ฒ-๐˜ƒ๐—ฎ๐—น๐—ถ๐—ฑ๐—ฎ๐˜๐—ฒ๐—ฑ ๐—ฎ๐—ป๐˜๐—ถ๐—ฏ๐—ผ๐—ฑ๐˜† ๐—ฝ๐—ฎ๐—ป๐—ฒ๐—น๐˜€ (๐˜๐—ผ๐˜๐—ฎ๐—น ๐—ฎ๐—ป๐—ฑ ๐—ฝ๐—ต๐—ผ๐˜€๐—ฝ๐—ต๐—ผ-๐—ฝ๐—ฟ๐—ผ๐˜๐—ฒ๐—ถ๐—ป).

Picture of Dr. Beena Punnamoottil

Dr. Beena Punnamoottil

VP Global Head Proteomics

Follow on LinkedIn
Picture of Dr. Jan Detmers

Dr. Jan Detmers

VP Global BioAnalysis

Follow on LinkedIn